NASDAQ:IMCR Immunocore Q1 2024 Earnings Report $35.27 -0.78 (-2.16%) Closing price 04:00 PM EasternExtended Trading$35.26 -0.02 (-0.04%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Immunocore EPS ResultsActual EPS-$0.49Consensus EPS -$0.37Beat/MissMissed by -$0.12One Year Ago EPS-$0.35Immunocore Revenue ResultsActual Revenue$70.30 millionExpected Revenue$70.72 millionBeat/MissMissed by -$420.00 thousandYoY Revenue Growth+27.60%Immunocore Announcement DetailsQuarterQ1 2024Date5/8/2024TimeBefore Market OpensConference Call DateWednesday, May 8, 2024Conference Call Time7:00AM ETUpcoming EarningsImmunocore's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Immunocore Earnings HeadlinesImmunocore Holdings plc (IMCR) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comImmunocore Holdings ADR Earns IBD Rating UpgradeJuly 10, 2025 | msn.comTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trillions in oil, gas, lithium, and land rights. Whitney Tilson breaks it all down, and shows how everyday Americans can grab a stake. His urgent new briefing explains "The US: IPO"... and how to get in before the looming federal deadline.July 24 at 2:00 AM | Stansberry Research (Ad)Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS RegionsJune 30, 2025 | finance.yahoo.comEr-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS RegionsJune 30, 2025 | globenewswire.comIMCR - Immunocore Holdings PLC ADR Ownership | MorningstarJune 28, 2025 | morningstar.comMSee More Immunocore Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunocore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunocore and other key companies, straight to your email. Email Address About ImmunocoreImmunocore (NASDAQ:IMCR) Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.View Immunocore ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?Microsoft’s AI Bet Faces a Major Test This Earnings SeasonAmazon Stock Rally Hits New Highs: Buy Into Earnings?TSLA Earnings Week: Can Tesla Break Through $350?Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets Upcoming Earnings Charter Communications (7/25/2025)AON (7/25/2025)ENI (7/25/2025)HCA Healthcare (7/25/2025)ICICI Bank (7/25/2025)NatWest Group (7/25/2025)Phillips 66 (7/25/2025)Southern Copper (7/25/2025)Cadence Design Systems (7/28/2025)Enterprise Products Partners (7/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
